SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic PTP4A3 through Chromatin Remodeling in t(4;14) Multiple Myeloma
- 18 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (9), 2332-2344
- https://doi.org/10.1158/0008-5472.can-20-2946
Abstract
NSD2 is the primary oncogenic driver in t(4;14) multiple myeloma. Using SILAC-based mass-spectrometry, we demonstrate a novel role of NSD2 in chromatin remodelling through its interaction with the SWI/SNF ATPase subunit SMARCA2. SMARCA2 was primarily expressed in t(4;14) myeloma cells, and its interaction with NSD2 was non-canonical and independent of the SWI/SNF complex. RNA-sequencing identified PTP4A3 as a downstream target of NSD2 and mapped NSD2-SMARCA2 complex on PTP4A3 promoter. This led to a focal increase in the permissive H3K36me2 mark and transcriptional activation of PTP4A3. High levels of PTP4A3 maintained MYC expression and correlated with a 54-gene MYC signature in t(4;14) multiple myeloma. Importantly, this mechanism was druggable by targeting the bromodomain of SMARCA2 using the specific BET inhibitor PFI-3, leading to the displacement of NSD2 from PTP4A3 promoter and inhibiting t(4;14) myeloma cell viability. In vivo, treatment with PFI-3 reduced the growth of t(4;14) xenograft tumors. Together, our study reveals an interplay between histone modifying enzymes and chromatin remodelers in the regulation of myeloma-specific genes that can be clinically intervened.Keywords
Other Versions
Funding Information
- Singapore Ministry of Education's Tier 3 (MOE2014-T3-1-006)
- National Medical Research Council (NMRC/OFYIRG/0039/2017)
This publication has 54 references indexed in Scilit:
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancyNature Genetics, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic ProgrammingMolecular Cell, 2011
- Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myelomaLeukemia, 2011
- The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cellsBlood, 2011
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene listsNucleic Acids Research, 2008
- The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressorBlood, 2008
- The multiple myeloma–associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicityBlood, 2008
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005